CYCN - Cyclerion Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.8900
-0.0400 (-2.07%)
At close: 4:00PM EST

1.8800 -0.01 (-0.53%)
After hours: 5:20PM EST

Stock chart is not supported by your current browser
Previous Close1.9300
Open1.9500
Bid1.8200 x 2900
Ask1.9100 x 1000
Day's Range1.8900 - 2.0200
52 Week Range1.6900 - 22.8500
Volume431,201
Avg. Volume538,214
Market Cap52.187M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.6550
Earnings DateAug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • GlobeNewswire

    Cyclerion to Present at the Evercore ISI 2nd Annual HealthCONx Conference

    CAMBRIDGE, Mass., Nov. 27, 2019 -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate.

  • Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View
    Zacks

    Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View

    Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.

  • Benzinga

    The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 30.) Allergan plc (NYSE: AGN ) Arrowhead Pharmaceuticals ...

  • MarketWatch

    Cyclerion's stock plummets to pace premarket losers after diabetes treatment study missed primary endpoint

    Shares of Cyclerion Therapeutics Inc. plummeted 71% toward a record low Wednesday, to pace all premarket losers, after the biopharmaceutical company said a Phase 2 trial of its diabetes treatment missed the primary endpoint. The company said the Phase 2 proof-of-concept study of praliciguat, which is a once-daily, orally available stimulator in diabetic nephropathy did not meet statistical significance on its primary endpoint of reduction in albuminuria from baseline as compared with placebo. The company said, however, there was a trend toward improvement and improvements were observed in patients in several secondary measures associated with cardiovascular risk and kidney disease. Cyclerion said it still expects to "out-license" praliciguat for global development and commercialization. The stock, which went public in March, has run up 39.2% over the past three months through Tuesday, while the iShares Nasdaq Biotechnology ETF has gained 1.0% and the S&P 500 has edged up 0.8%.

  • Ironwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial
    American City Business Journals

    Ironwood spinout Cyclerion plans 30 layoffs after drug fails mid-stage trial

    New biopharma startup Cyclerion Therapeutics has stumbled out of the gate, disclosing Wednesday that one of its lead drug candidates failed in a mid-stage study.

  • GlobeNewswire

    Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced topline results from its Phase 2 proof-of-concept study of praliciguat, a once-daily, orally available systemic sGC stimulator, in diabetic nephropathy. The study did not meet statistical significance on its primary endpoint of reduction in albuminuria from baseline as compared to placebo, measured by urine albumin creatinine ratio (UACR), but there was a trend toward improvement across the total intention-to-treat (ITT) study population.

  • GlobeNewswire

    Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced topline results from its CAPACITY Phase 2 proof-of-concept study of praliciguat, a once-daily, orally available systemic sGC stimulator, in heart failure with preserved ejection fraction (HFpEF). The study did not meet statistical significance on its primary endpoint of improved exercise capacity from baseline as compared to placebo, measured by cardiopulmonary exercise testing (CPET).

  • GlobeNewswire

    Cyclerion Therapeutics and Collaborators to Present New Research on the Sickle Cell Disease Patient Journey at Upcoming Medical Meetings

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced upcoming medical meeting presentations highlighting its commitment to sickle cell disease patients and supporting its therapeutic approach to treating the disease through sGC stimulation. Cyclerion will present at the Annual National Convention of the Sickle Cell Disease Association of America (SCDAA), held October 9-12 in Baltimore, and at the Annual Sickle Cell Disease and Thalassaemia Conference (ASCAT), held October 21-23 in London. Cyclerion and its collaborators will present new research from a sickle cell disease patient journey project.

  • Read This Before Selling Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares
    Simply Wall St.

    Read This Before Selling Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • GlobeNewswire

    Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it will host a webcast investor event, to be held in New York City, on Tuesday, September 17, 2019 from 8:00 a.m. to 10:00 a.m. Eastern Time. This first Cyclerion live investor event will focus on praliciguat, the company’s investigational, orally administered, once-daily systemic sGC stimulator designed for the treatment of serious cardiometabolic diseases. External subject matter experts – Dr. James Udelson of Tufts Medical Center and Dr. Barbara Gillespie of the University of North Carolina and Covance – and members of Cyclerion’s leadership team will review the role of the nitric oxide/sGC system in cardiorenal physiology, the praliciguat development program, and the ongoing Phase 2 clinical studies investigating praliciguat as a potential treatment for diabetic nephropathy and for HFpEF.

  • GlobeNewswire

    Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months

    – Two praliciguat Phase 2 studies for diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) on track for data readouts in Q4 2019 – – Phase 2 study.

  • Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates
    Zacks

    Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates

    Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.

  • What Kind Of Shareholders Own Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)?
    Simply Wall St.

    What Kind Of Shareholders Own Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)?

    A look at the shareholders of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) can tell us which group is most powerful...

  • GlobeNewswire

    Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that three upcoming data presentations will be made on two of its clinical-stage pipeline candidates during the 9th International Conference on cGMP, held June 14-16 in Mainz, Germany. One presentation will discuss the results of a series of preclinical studies on IW-6463, Cyclerion’s central nervous system (CNS)-penetrant sGC stimulator designed to address serious neurodegenerative diseases, showing an association between treatment with IW-6463 and decreased markers of neuroinflammation, enhanced blood flow in brain regions associated with cognition, improved dendritic spine density and structure and restored cognitive performance.

  • Ironwood Initiates Dosing in Mid-Stage Study for MD-7246
    Zacks

    Ironwood Initiates Dosing in Mid-Stage Study for MD-7246

    Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.

  • GuruFocus.com

    3 Spinoff Stocks Worth Your Attention

    Joel Greenblatt (Trades, Portfolio)'s "You Can Be a Stock Market Genius" prompted many investors to follow spinoff stocks with close attention. Gurus like Peter Lynch, Charlie Munger (Trades, Portfolio) and Seth Klarman (Trades, Portfolio) do as well. Warning! GuruFocus has detected 1 Warning Sign with BCS.

  • GlobeNewswire

    Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced upcoming data presentations supporting its therapeutic approach in sickle cell disease (SCD) during the 24th European Hematology Association (EHA) Congress, held June 13-16 in Amsterdam. The company will also present an overview of olinciguat, its sGC stimulator under clinical investigation in the Phase 2 STRONG SCD study as a potential treatment for sickle cell disease, at the 13th Annual Sickle Cell Disease Research and Educational Symposium, hosted by the Foundation for Sickle Cell Disease Research (FSCDR), and held June 7-9 in Fort Lauderdale, Florida.

  • GlobeNewswire

    Cyclerion Therapeutics Provides a Corporate and Pipeline Overview as a Newly Launched Public Biopharmaceutical Company

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today provided a general corporate and pipeline overview, as well as financial results for the first quarter of 2019. “Cyclerion launched with the mission of developing life changing medicines for patients suffering from serious and orphan diseases through the modulation of soluble guanylate cyclase,” said Peter Hecht, Ph.D., chief executive officer of Cyclerion. “Our team is advancing a pipeline of differentiated and wholly owned sGC stimulator therapeutic candidates with compelling preclinical and clinical data.

  • GlobeNewswire

    Cyclerion to Host Corporate Overview Call on May 13, 2019

    Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it will host a conference call and live audio webcast on Monday, May 13, 2019 at 8:30 a.m. Eastern Time. For its first webcast conference call as a public company, Cyclerion intends to provide a general corporate overview and discuss its clinical and preclinical development pipeline.

  • GlobeNewswire

    Cyclerion Launches as Clinical-Stage Biopharmaceutical Company Harnessing the Power of Soluble Guanylate Cyclase (sGC) Pharmacology for Treatment of Serious and Orphan Diseases

    Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced its launch as an independent, publicly traded clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. “We are excited to unleash the terrific Cyclerion team and further our laser-focused mission to advance tailored sGC stimulators to patients with serious and orphan diseases,” said Peter Hecht, chief executive officer of Cyclerion.